Novelix Pharma.

Market Cap: Micro Cap
Industry: Retailing
ISIN: INE314I01036
NSEID:
BSEID: 536565

INR

56.77

-2.98 (-4.99%)

BSENSE

Dec 05

BSE+NSE Vol: 18.82 k

{
  "main_header": {
    "sid": 200695,
    "name": "Novelix Pharma.",
    "stock_name": "Novelix Pharma.",
    "full_name": "Novelix Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/novelix-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "56.77",
    "chg": -2.98,
    "chgp": "-4.99%",
    "dir": -1,
    "prev_price": "59.75",
    "mcapval": "92.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 536565,
    "symbol": "",
    "ind_name": "Retailing",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE314I01036",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "18.82 k",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/novelix-pharma-200695-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Novelix Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novelix-pharmaceuticals-faces-severe-selling-pressure-hits-lower-circuit-amid-market-turmoil-3748017",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NovelixPharmace_only_sellers_3748017.png",
        "date": "2025-12-05 09:30:20",
        "description": "Novelix Pharmaceuticals has encountered significant selling pressure, with the stock registering a sharp decline of 4.99% today and exhibiting a distinct absence of buyers. This marks the third consecutive day of losses, reflecting a sustained period of distress selling that has weighed heavily on investor sentiment."
      },
      {
        "title": "Novelix Pharmaceuticals: Analytical Review Highlights Key Shifts in Market Assessment",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/novelix-pharmaceuticals-downgraded-to-sell-amid-mixed-technicals-and-valuation-concerns-3747716",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NovelixPharmace_mojoScore_3747716.png",
        "date": "2025-12-05 08:06:04",
        "description": "Novelix Pharmaceuticals has undergone a notable revision in its market evaluation, reflecting shifts across multiple analytical parameters including quality, valuation, financial trends, and technical indicators. This article examines the underlying factors influencing these changes and their implications for investors within the retailing sector."
      },
      {
        "title": "How has been the historical performance of Novelix Pharma.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-novelix-pharma-3747097",
        "imagepath": "",
        "date": "2025-12-04 22:46:23",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Operating Performance Trends</strong></p>\n<p>Net sales for Novelix Pharma. peaked around the fiscal year ending March 2018 at approximately ₹10.50 crores but have since shown a gradual decline, falling to ₹8.61 crores by March 2022. The total operating income mirrored this trend, with a notable drop from ₹10.50 crores in 2018 to ₹8.61 crores in 2022. The company’s cost structure reveals a significant reliance on the purchase of finished goods, which constituted the largest share of expenditure, increasing from ₹4.12 crores in 2016 to ₹8.26 crores in 2022. Raw material costs remained relatively low but fluctuated, while employee costs showed a modest increase over the years.</p>\n<p>Operating profit margins have deteriorated sharply, with the company reporting negative margins cons..."
      },
      {
        "title": "Novelix Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novelix-pharmaceuticals-faces-severe-selling-pressure-hits-lower-circuit-amid-market-turmoil-3745843",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NovelixPharmace_only_sellers_3745843.png",
        "date": "2025-12-04 09:35:28",
        "description": "Novelix Pharmaceuticals Ltd experienced a sharp decline today, marked by exclusive selling activity and a lower circuit lock at Rs 59.75. The stock’s performance contrasts starkly with the broader market, signalling distress selling and heightened investor caution."
      },
      {
        "title": "Novelix Pharmaceuticals Faces Intense Selling Pressure Amid Lower Circuit Lockdown",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novelix-pharmaceuticals-faces-severe-selling-pressure-amid-lower-circuit-lockdown-3743312",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NovelixPharmace_only_sellers_3743312.png",
        "date": "2025-12-03 09:40:26",
        "description": "Novelix Pharmaceuticals Ltd experienced a severe downturn on 3 Dec 2025, marked by an exclusive presence of sell orders and a lower circuit lock that halted any buying activity. The stock’s performance sharply contrasted with broader market trends, signalling distress selling and heightened investor caution within the retailing sector."
      },
      {
        "title": "Novelix Pharmaceuticals Surges with Unprecedented Buying Interest and Upper Circuit Lock",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novelix-pharmaceuticals-hits-upper-circuit-amid-unprecedented-buying-frenzy-3740947",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NovelixPharmace_only_buyers_3740947.png",
        "date": "2025-12-02 09:35:23",
        "description": "Novelix Pharmaceuticals has witnessed extraordinary buying momentum, locking in an upper circuit with exclusively buy orders in the queue. This remarkable demand, coupled with a string of consecutive gains, signals a potential multi-day circuit scenario for the retailing sector stock."
      },
      {
        "title": "Novelix Pharmaceuticals Surges with Unprecedented Buying Interest and Upper Circuit Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novelix-pharmaceuticals-hits-upper-circuit-amid-unprecedented-buying-interest-3737831",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NovelixPharmace_only_buyers_3737831.png",
        "date": "2025-12-01 09:55:14",
        "description": "Novelix Pharmaceuticals has captured market attention with extraordinary buying interest, registering an upper circuit scenario marked by a complete absence of sellers. This rare market phenomenon signals robust demand and the potential for sustained gains over multiple trading sessions."
      },
      {
        "title": "Novelix Pharmaceuticals Surges with Unprecedented Buying Interest and Upper Circuit Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novelix-pharmaceuticals-surges-on-unprecedented-buying-interest-hits-upper-circuit-3734961",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/NovelixPharmace_only_buyers_3734961.png",
        "date": "2025-11-28 09:40:17",
        "description": "Novelix Pharmaceuticals has demonstrated extraordinary buying interest, registering a significant price surge accompanied by an upper circuit scenario with exclusively buy orders in the queue. This remarkable momentum highlights a potential multi-day circuit trend, underscoring robust demand in the retailing sector."
      },
      {
        "title": "Is Novelix Pharma. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-novelix-pharma-overvalued-or-undervalued-3734472",
        "imagepath": "",
        "date": "2025-11-28 08:07:11",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Valuation Metrics Indicate Elevated Pricing</strong></p>\n<p>Novelix Pharma currently trades at a price-to-earnings (PE) ratio exceeding 97, a figure that significantly surpasses typical industry standards and peer averages. This elevated PE ratio suggests that investors are pricing in substantial future growth or are paying a premium for the stock. The price-to-book (P/B) ratio stands at 3.60, which, while not extreme, is above the average for many pharmaceutical companies, indicating that the market values the company’s net assets at a considerable premium.</p>\n<p>Enterprise value multiples further reinforce this view. The EV to EBIT and EV to EBITDA ratios are approximately 70.4 and 68.3 respectively, both markedly higher than those of comparable firms in the sector. Such multiples imply t..."
      }
    ],
    "total": 96,
    "sid": "200695",
    "stock_news_url": "https://www.marketsmojo.com/news/novelix-pharmaceuticals-200695"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "15-Nov-2025",
      "details": "Submission of Newspaper publication.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Resignation of Director",
      "datetime": "14-Nov-2025",
      "details": "Submission of intimation of Resignation of Independent Director.",
      "source": "BSE"
    },
    {
      "caption": "Intimation Of Reconstitution Of Committees.",
      "datetime": "14-Nov-2025",
      "details": "Submission of intimation of reconstitution of committees.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Novelix Pharmaceuticals Ltd has declared <strong>3%</strong> dividend, ex-date: 16 Aug 12",
          "dt": "2012-08-16",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Novelix Pharmaceuticals Ltd has announced <strong>10:1</strong> stock split, ex-date: 04 Oct 10",
          "dt": "2010-10-04",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Novelix Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses

2025-12-05 09:30:20

Novelix Pharmaceuticals has encountered significant selling pressure, with the stock registering a sharp decline of 4.99% today and exhibiting a distinct absence of buyers. This marks the third consecutive day of losses, reflecting a sustained period of distress selling that has weighed heavily on investor sentiment.

Novelix Pharmaceuticals: Analytical Review Highlights Key Shifts in Market Assessment

2025-12-05 08:06:04

Novelix Pharmaceuticals has undergone a notable revision in its market evaluation, reflecting shifts across multiple analytical parameters including quality, valuation, financial trends, and technical indicators. This article examines the underlying factors influencing these changes and their implications for investors within the retailing sector.

How has been the historical performance of Novelix Pharma.?

2025-12-04 22:46:23

Revenue and Operating Performance Trends

Net sales for Novelix Pharma. peaked around the fiscal year ending March 2018 at approximately ₹10.50 crores but have since shown a gradual decline, falling to ₹8.61 crores by March 2022. The total operating income mirrored this trend, with a notable drop from ₹10.50 crores in 2018 to ₹8.61 crores in 2022. The company’s cost structure reveals a significant reliance on the purchase of finished goods, which constituted the largest share of expenditure, increasing from ₹4.12 crores in 2016 to ₹8.26 crores in 2022. Raw material costs remained relatively low but fluctuated, while employee costs showed a modest increase over the years.

Operating profit margins have deteriorated sharply, with the company reporting negative margins cons...

Novelix Pharmaceuticals Faces Intense Selling Pressure Amid Consecutive Losses

2025-12-04 09:35:28

Novelix Pharmaceuticals Ltd experienced a sharp decline today, marked by exclusive selling activity and a lower circuit lock at Rs 59.75. The stock’s performance contrasts starkly with the broader market, signalling distress selling and heightened investor caution.

Novelix Pharmaceuticals Faces Intense Selling Pressure Amid Lower Circuit Lockdown

2025-12-03 09:40:26

Novelix Pharmaceuticals Ltd experienced a severe downturn on 3 Dec 2025, marked by an exclusive presence of sell orders and a lower circuit lock that halted any buying activity. The stock’s performance sharply contrasted with broader market trends, signalling distress selling and heightened investor caution within the retailing sector.

Novelix Pharmaceuticals Surges with Unprecedented Buying Interest and Upper Circuit Lock

2025-12-02 09:35:23

Novelix Pharmaceuticals has witnessed extraordinary buying momentum, locking in an upper circuit with exclusively buy orders in the queue. This remarkable demand, coupled with a string of consecutive gains, signals a potential multi-day circuit scenario for the retailing sector stock.

Novelix Pharmaceuticals Surges with Unprecedented Buying Interest and Upper Circuit Momentum

2025-12-01 09:55:14

Novelix Pharmaceuticals has captured market attention with extraordinary buying interest, registering an upper circuit scenario marked by a complete absence of sellers. This rare market phenomenon signals robust demand and the potential for sustained gains over multiple trading sessions.

Novelix Pharmaceuticals Surges with Unprecedented Buying Interest and Upper Circuit Momentum

2025-11-28 09:40:17

Novelix Pharmaceuticals has demonstrated extraordinary buying interest, registering a significant price surge accompanied by an upper circuit scenario with exclusively buy orders in the queue. This remarkable momentum highlights a potential multi-day circuit trend, underscoring robust demand in the retailing sector.

Is Novelix Pharma. overvalued or undervalued?

2025-11-28 08:07:11

Valuation Metrics Indicate Elevated Pricing

Novelix Pharma currently trades at a price-to-earnings (PE) ratio exceeding 97, a figure that significantly surpasses typical industry standards and peer averages. This elevated PE ratio suggests that investors are pricing in substantial future growth or are paying a premium for the stock. The price-to-book (P/B) ratio stands at 3.60, which, while not extreme, is above the average for many pharmaceutical companies, indicating that the market values the company’s net assets at a considerable premium.

Enterprise value multiples further reinforce this view. The EV to EBIT and EV to EBITDA ratios are approximately 70.4 and 68.3 respectively, both markedly higher than those of comparable firms in the sector. Such multiples imply t...

View All News